Neumora Therapeutics Inc (NMRA)

$2.69 -0.17 (-5.94%)
Market Cap 477.88M
Revenue (ttm) 0.00
Net Income (ttm) -243.79M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.15
Volume 1,216,900
Avg Vol 1,684,798
Day's Range N/A - N/A
Shares Out 167.09M
Stochastic %K 48%
Beta 2.98
Analysts Sell
Price Target $8.50

Company Profile

Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases in the United States. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder. It also develops NMRA-511 that is in phase 1 clinical trials in patients with agitation associa...

Industry: Biotechnology
Sector: Healthcare
Phone: 857 760 0900
Address:
490 Arsenal Way, Suite 200, Watertown, United States
Mrstock2255
Mrstock2255 Nov. 13 at 11:10 PM
$NFLX $NGL $NHTC $NMRA $NOG
0 · Reply
resistancebreakers
resistancebreakers Nov. 12 at 9:36 PM
$NMRA
0 · Reply
InvestorCG
InvestorCG Nov. 12 at 7:33 PM
$NMRA that was a joke of a shake during presentation. Presentation time of 1/2 hour is too short to go over every drug in our pipeline. They need full presentation using their Powerpoint presentation that was FINALIZED YESTERDAY. https://ir.neumoratx.com/static-files/346aaaf8-b4ff-4167-b0c2-da453cf23b5c
0 · Reply
GaryH59
GaryH59 Nov. 12 at 6:11 PM
$NMRA DEC 2025 calls worth it at .40?
0 · Reply
InvestorCG
InvestorCG Nov. 12 at 5:50 PM
$NMRA preview in advance. I don't think this packet has been seen before. https://ir.neumoratx.com/static-files/346aaaf8-b4ff-4167-b0c2-da453cf23b5c
0 · Reply
Xmandingo
Xmandingo Nov. 12 at 4:30 PM
$NMRA she wants to breakout
0 · Reply
InvestorCG
InvestorCG Nov. 12 at 2:44 PM
$NMRA For those who are interested in the next level weight loss drugs such as $MTSR $NVO $PFE and others, $NRMA is presenting at Stifel this afternoon. Would hope for a stock upgrade from them after presentation.
0 · Reply
SwingEdge
SwingEdge Nov. 12 at 5:42 AM
$NMRA anyone else continuing to accumulate around this area?
1 · Reply
Mr_GA
Mr_GA Nov. 12 at 1:55 AM
$NMRA Maybe we will get some good news out of the Stifel 2025 Healthcare Conference tomorrow? https://ir.neumoratx.com/events/event-details/stifel-2025-healthcare-conference
0 · Reply
InvestorCG
InvestorCG Nov. 11 at 8:29 PM
$NMRA see if we see some high volume crosses EOD like we have last few days.
0 · Reply
Latest News on NMRA
Neumora Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update

Nov 6, 2025, 7:00 AM EST - 8 days ago

Neumora Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update

Neumora Therapeutics to Participate in Upcoming Conferences in November

Nov 3, 2025, 7:00 AM EST - 11 days ago

Neumora Therapeutics to Participate in Upcoming Conferences in November

Neumora Therapeutics, Inc. (NMRA) Discusses NMRA-215 Preclinical Results and Portfolio Updates, Including Obesity and Alzheimer's Disease Programs Transcript

Oct 27, 2025, 1:57 PM EDT - 17 days ago

Neumora Therapeutics, Inc. (NMRA) Discusses NMRA-215 Preclinical Results and Portfolio Updates, Including Obesity and Alzheimer's Disease Programs Transcript

Neumora Therapeutics Announces Initiation of Phase 1 Clinical Study of M4 Positive Allosteric Modulator NMRA-898

Oct 27, 2025, 7:00 AM EDT - 18 days ago

Neumora Therapeutics Announces Initiation of Phase 1 Clinical Study of M4 Positive Allosteric Modulator NMRA-898

Neumora Therapeutics Announces Class-Leading Weight Loss Demonstrated with NMRA-215 in Preclinical Diet-Induced Obesity Model

Oct 27, 2025, 6:30 AM EDT - 18 days ago

Neumora Therapeutics Announces Class-Leading Weight Loss Demonstrated with NMRA-215 in Preclinical Diet-Induced Obesity Model

Neumora Therapeutics to Host Virtual R&D Day on October 27

Oct 1, 2025, 7:00 AM EDT - 6 weeks ago

Neumora Therapeutics to Host Virtual R&D Day on October 27

Neumora Therapeutics to Participate in Upcoming Conferences in September

Sep 2, 2025, 7:00 AM EDT - 2 months ago

Neumora Therapeutics to Participate in Upcoming Conferences in September

Neumora Therapeutics, Inc. (NMRA) Q2 2025 Earnings Call Transcript

Aug 7, 2025, 2:41 AM EDT - 3 months ago

Neumora Therapeutics, Inc. (NMRA) Q2 2025 Earnings Call Transcript

Neumora Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update

Aug 6, 2025, 4:05 PM EDT - 3 months ago

Neumora Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update

Neumora Therapeutics to Report Second Quarter 2025 Financial Results on Wednesday, August 6, 2025

Jul 23, 2025, 7:00 AM EDT - 4 months ago

Neumora Therapeutics to Report Second Quarter 2025 Financial Results on Wednesday, August 6, 2025

Neumora Therapeutics Announces Initiation of Phase 1 Clinical Study of M4 Positive Allosteric Modulator NMRA-861

Jul 9, 2025, 7:00 AM EDT - 4 months ago

Neumora Therapeutics Announces Initiation of Phase 1 Clinical Study of M4 Positive Allosteric Modulator NMRA-861

Neumora Therapeutics, Inc. (NMRA) Q1 2025 Earnings Call Transcript

May 12, 2025, 7:18 PM EDT - 6 months ago

Neumora Therapeutics, Inc. (NMRA) Q1 2025 Earnings Call Transcript

Neumora Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

May 12, 2025, 4:01 PM EDT - 6 months ago

Neumora Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

Neumora Therapeutics to Report First Quarter 2025 Financial Results on Monday, May 12, 2025

Apr 28, 2025, 7:00 AM EDT - 7 months ago

Neumora Therapeutics to Report First Quarter 2025 Financial Results on Monday, May 12, 2025

NMRA Deadline: NMRA Investors with Losses in Excess of $100K Have Opportunity to Lead Neumora Therapeutics, Inc. Securities Lawsuit First Filed by The Firm

Apr 4, 2025, 4:05 PM EDT - 7 months ago

NMRA Deadline: NMRA Investors with Losses in Excess of $100K Have Opportunity to Lead Neumora Therapeutics, Inc. Securities Lawsuit First Filed by The Firm

NMRA Deadline: NMRA Investors Have Opportunity to Lead Neumora Therapeutics, Inc. Securities Lawsuit First Filed by The Firm

Mar 30, 2025, 4:00 PM EDT - 8 months ago

NMRA Deadline: NMRA Investors Have Opportunity to Lead Neumora Therapeutics, Inc. Securities Lawsuit First Filed by The Firm

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of April 7, 2025 in Neumora Therapeutics, Inc. Lawsuit - NMRA

Mar 27, 2025, 5:45 AM EDT - 8 months ago

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of April 7, 2025 in Neumora Therapeutics, Inc. Lawsuit - NMRA

NMRA Investors Have Opportunity to Lead Neumora Therapeutics, Inc. Securities Lawsuit First Filed by The Firm

Mar 26, 2025, 2:19 AM EDT - 8 months ago

NMRA Investors Have Opportunity to Lead Neumora Therapeutics, Inc. Securities Lawsuit First Filed by The Firm

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Neumora Therapeutics

Mar 15, 2025, 9:29 AM EDT - 8 months ago

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Neumora Therapeutics

SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Neumora Therapeutics

Mar 13, 2025, 10:19 AM EDT - 8 months ago

SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Neumora Therapeutics

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of April 7, 2025 in Neumora Therapeutics, Inc. Lawsuit – NMRA

Mar 6, 2025, 12:17 PM EST - 9 months ago

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of April 7, 2025 in Neumora Therapeutics, Inc. Lawsuit – NMRA

Neumora Therapeutics to Present at Leerink Global Healthcare Conference

Mar 4, 2025, 8:30 AM EST - 9 months ago

Neumora Therapeutics to Present at Leerink Global Healthcare Conference

Neumora Therapeutics, Inc. (NMRA) Q4 2024 Earnings Call Transcript

Mar 3, 2025, 11:37 AM EST - 9 months ago

Neumora Therapeutics, Inc. (NMRA) Q4 2024 Earnings Call Transcript

Neumora Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Mar 3, 2025, 7:00 AM EST - 9 months ago

Neumora Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Investors in Neumora Therapeutics, Inc. Should Contact The Gross Law Firm Before April 7, 2025 to Discuss Your Rights - NMRA

Feb 27, 2025, 5:45 AM EST - 9 months ago

Investors in Neumora Therapeutics, Inc. Should Contact The Gross Law Firm Before April 7, 2025 to Discuss Your Rights - NMRA

Robbins LLP Reminds Neumora Therapeutics, Inc. (NMRA) Investors With Large Losses to Contact the Firm to Learn How They Can Recover for Their Losses

Feb 26, 2025, 8:46 PM EST - 9 months ago

Robbins LLP Reminds Neumora Therapeutics, Inc. (NMRA) Investors With Large Losses to Contact the Firm to Learn How They Can Recover for Their Losses

Investors in Neumora Therapeutics, Inc. Should Contact The Gross Law Firm Before April 7, 2025 to Discuss Your Rights – NMRA

Feb 26, 2025, 1:32 PM EST - 9 months ago

Investors in Neumora Therapeutics, Inc. Should Contact The Gross Law Firm Before April 7, 2025 to Discuss Your Rights – NMRA

Mrstock2255
Mrstock2255 Nov. 13 at 11:10 PM
$NFLX $NGL $NHTC $NMRA $NOG
0 · Reply
resistancebreakers
resistancebreakers Nov. 12 at 9:36 PM
$NMRA
0 · Reply
InvestorCG
InvestorCG Nov. 12 at 7:33 PM
$NMRA that was a joke of a shake during presentation. Presentation time of 1/2 hour is too short to go over every drug in our pipeline. They need full presentation using their Powerpoint presentation that was FINALIZED YESTERDAY. https://ir.neumoratx.com/static-files/346aaaf8-b4ff-4167-b0c2-da453cf23b5c
0 · Reply
GaryH59
GaryH59 Nov. 12 at 6:11 PM
$NMRA DEC 2025 calls worth it at .40?
0 · Reply
InvestorCG
InvestorCG Nov. 12 at 5:50 PM
$NMRA preview in advance. I don't think this packet has been seen before. https://ir.neumoratx.com/static-files/346aaaf8-b4ff-4167-b0c2-da453cf23b5c
0 · Reply
Xmandingo
Xmandingo Nov. 12 at 4:30 PM
$NMRA she wants to breakout
0 · Reply
InvestorCG
InvestorCG Nov. 12 at 2:44 PM
$NMRA For those who are interested in the next level weight loss drugs such as $MTSR $NVO $PFE and others, $NRMA is presenting at Stifel this afternoon. Would hope for a stock upgrade from them after presentation.
0 · Reply
SwingEdge
SwingEdge Nov. 12 at 5:42 AM
$NMRA anyone else continuing to accumulate around this area?
1 · Reply
Mr_GA
Mr_GA Nov. 12 at 1:55 AM
$NMRA Maybe we will get some good news out of the Stifel 2025 Healthcare Conference tomorrow? https://ir.neumoratx.com/events/event-details/stifel-2025-healthcare-conference
0 · Reply
InvestorCG
InvestorCG Nov. 11 at 8:29 PM
$NMRA see if we see some high volume crosses EOD like we have last few days.
0 · Reply
InvestorCG
InvestorCG Nov. 11 at 3:30 PM
$NMRA low volume slide here. Daytraders didn't like the last minute drop at EOD.
0 · Reply
Xmandingo
Xmandingo Nov. 11 at 4:59 AM
$NMRA not only a gap fill … but a text book cup and handle!!!
0 · Reply
StockConsultant
StockConsultant Nov. 11 at 4:01 AM
$NMRA Neumora Therapeutics stock, breakout watch
1 · Reply
SwingEdge
SwingEdge Nov. 10 at 8:52 PM
$NMRA clearing this 3$ area with some volume would be the catalyst for a move to 4-5$+ area. 2.40-2.60 is a great accumulation area for the next leg up
0 · Reply
Mr_GA
Mr_GA Nov. 10 at 8:26 PM
$NMRA Maybe Neumora will eventually achieve HC Wainwright's $18 price target? https://www.investing.com/news/analyst-ratings/hc-wainwright-maintains-buy-rating-on-neumora-stock-ahead-of-obesity-drug-data-93CH-4304410
0 · Reply
LongTermInvestingCKramer
LongTermInvestingCKramer Nov. 10 at 8:08 PM
$NMRA With potential best in class obesity drug can NMRA be 50 billion company? That makes the stock price at approximately 300$ Plus, there is more in pipeline.
1 · Reply
InvestorCG
InvestorCG Nov. 10 at 7:52 PM
$NMRA KOASTAL past test did not focus on the correct patient type population. KOASTAL 2 and 3 review of potential patients have been much stronger and a "higher quality of patient". This is for MDD - Major Depressive Disorder.
1 · Reply
InvestorCG
InvestorCG Nov. 10 at 7:49 PM
$NMRA FROM PRESENTATION: Alzheimer's data by mid 2026. Molecules allow for great flexibility for the Alzheimer's market as well.
0 · Reply
InvestorCG
InvestorCG Nov. 10 at 7:42 PM
$NMRA FROM PRESENTATION: $NMRA 215 can have heart/cardio benefits as well. Will test that afterwards. Obesity first.
0 · Reply
InvestorCG
InvestorCG Nov. 10 at 7:36 PM
$NMRA FROM CONFERENCE: Preclinical DIO results STRONGLY correlate (over 90%) with human models for obesity type tests. Nice!
0 · Reply
Xmandingo
Xmandingo Nov. 10 at 6:45 PM
$NMRA Can you say GAP FILL!?!
0 · Reply
kimberant
kimberant Nov. 10 at 5:06 PM
$NMRA The signal is 38th GARPS access to German GI buyers. Importance is playbook clarity awareness then pilots then reorders on 30 to 90 day cycles which builds a 2025 base and strengthens strategic options entering 2026
0 · Reply